UCART22 + CLLS52
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Acute Lymphoblastic Leukemia
Conditions
B-cell Acute Lymphoblastic Leukemia
Trial Timeline
Oct 14, 2019 → Jun 30, 2026
NCT ID
NCT04150497About UCART22 + CLLS52
UCART22 + CLLS52 is a phase 1/2 stage product being developed by Cellectis for B-cell Acute Lymphoblastic Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04150497. Target conditions include B-cell Acute Lymphoblastic Leukemia.
What happened to similar drugs?
3 of 20 similar drugs in B-cell Acute Lymphoblastic Leukemia were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
9
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04150497 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in B-cell Acute Lymphoblastic Leukemia